6-(4-甲氧基苯基)吡啶-3-胺 | 52057-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(4-甲氧基苯基)吡啶-3-胺
• 英文名称: 6-(4-methoxyphenyl)-pyridin-3-ylamine
• 英文别名: 6-(4-Methoxyphenyl)pyridin-3-amine
• CAS: 52057-98-4
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: DUYYTOFLIZLBKH-UHFFFAOYSA-N

物化性质

• 熔点：
  110-112
• 沸点：
  377.4±32.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-(4-甲氧基苯基)吡啶-3-胺 、 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.25h， 生成
  参考文献：
  名称：

  新型吡唑酰胺作为有效杀菌剂候选物的发现及其作用方式的评估

  摘要：

  应用基于支架跳跃的合理分子设计策略发现新的先导分子，然后设计、合成、表征和评估了一系列新型吡唑酰胺衍生物的抗真菌活性。生物测定结果表明，一些目标化合物如S3、S12和S26表现出良好的体内抗真菌活性；其中，S26在 100 μg/mL 时表现出值得称道的体内保护活性，对黄瓜灰霉病菌的抑制率为 89% ，与阳性对照啶酰菌胺、异吡唑啉和fluxapyroxad 相当。显微镜观察表明S26影响真菌的正常生长。荧光猝灭分析和 SDH（琥珀酸脱氢酶）酶抑制研究证实S26可能不是 SDH 抑制剂。基于诱导植物防御反应测试，S26增强了黄瓜上RBOH、WRKY6、WRKY30、PR1和PAL防御相关基因表达和防御相关酶苯丙氨酸解氨酶 (PAL) 表达的积累。这些发现支持S26不仅表现出直接的杀菌活性，而且表现出植物先天免疫刺激活性，它可以作为一种有前途的植物防御相关杀菌剂候选物。

  DOI：

  10.1021/acs.jafc.2c00092
• 作为产物：
  描述：

  2-溴-5-硝基吡啶 在 potassium phosphate monohydrate 、 5%-palladium/activated carbon 、 四丁基溴化铵 、 氢气 、 palladium diacetate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 6-(4-甲氧基苯基)吡啶-3-胺
  参考文献：
  名称：

  Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity

  摘要：

  Receptor tyrosine kinase PDGFR alpha is often constitutively activated in various tumours and is regarded as a drug target. Here, we present a collection of 2,6,9-trisubstituted purines with nanomolar potency against PDGFR alpha and strong and selective cytotoxicity in the human eosinophilic leukaemia cell line EOL-1 that expresses the FIP1L1-PDGFRA oncogene. In treated EOL-1 cells, the example compound 14q inhibited the autophosphorylation of PDGFR alpha and the phosphorylation of STAT3 and ERK1/2. Interestingly, we observed pronounced and even increased effects of 14q on PDGFR alpha and some of its downstream signalling pathways after drug washout. In accordance with suppressed PDGFR alpha signalling, treated cells were arrested in the G1 phase of the cell cycle and eventually underwent apoptosis. Our results show that substituted purines can be used as specific modulators of eosinophilic leukaemia. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111663

文献信息

• [EN] ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS<br/>[FR] DÉRIVÉS DE L'ISOQUINOLINONE UTILISÉS COMME ANTAGONISTES DES NK3
  申请人：LUNDBECK & CO AS H

  公开号：WO2009156339A1

  公开（公告）日：2009-12-30

  Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.

  提供了一般式I的异喹啉衍生物。这些化合物是NK3拮抗剂，可用于治疗精神病和精神分裂症等疾病。
• Agent for Treatment of Eye Diseases
  申请人：Kakizuka Akira

  公开号：US20140148416A1

  公开（公告）日：2014-05-29

  The present invention provides agents effective to treat eye diseases, pharmaceutical compositions comprising them, methods for preparing pharmaceuticals for treatment of eye diseases comprising using the agents, use of the agents in manufacture of pharmaceuticals for treatment of eye diseases and methods for treating eye diseases comprising administering the agents or the pharmaceutical compositions. The eye diseases treated by the present invention include particularly glaucoma, especially normal tension glaucoma, or retinitis pigmentosa. The present invention provides the compound of formula (I) wherein R is as defined in the description.

  本发明提供了治疗眼部疾病的有效药剂，包括它们的制药组合物，制备用于治疗眼部疾病的药物的方法，包括使用这些药剂，以及在制造用于治疗眼部疾病的药物时使用这些药剂的方法，以及通过给药这些药剂或药物组合物来治疗眼部疾病的方法。本发明治疗的眼部疾病包括青光眼，特别是正常张力青光眼，或色素性视网膜病变。本发明提供了式（I）的化合物，其中R在说明中定义。
• Naphthalene Derivative
  申请人：Kakizuka Akira

  公开号：US20130184241A1

  公开（公告）日：2013-07-18

  The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

  本发明提供了可以调节VCP活性的化合物。本发明提供了式(I)的化合物（其中R如描述中所定义）或其氧化物、酯、前药、药学上可接受的盐或溶剂。这些化合物可以调节VCP活性，因此可用于治疗VCP介导的疾病，如神经退行性疾病。
• Structure–activity relationship study of E6 as a novel necroptosis inducer
  作者：Jianfeng Mou、Ann Park、Yu Cai、Junying Yuan、Chengye Yuan

  DOI：10.1016/j.bmcl.2015.04.038

  日期：2015.8

  Necroptosis inducers represent a promising potential treatment for drug-resistant cancer. We herein describe the structure modification of E6, which was identified recently as a potent and selective necroptosis inducer. The studies described herein demonstrate for the first time that functionalized biphenyl derivatives possess necroptosis inducer activity. Furthermore, these studies have led to the identification of two promising compounds (5h and 5j) that can be used for further optimization studies as well as mechanism of action investigations. (C) 2015 Elsevier Ltd. All rights reserved.
• An Active, General, and Long-Lived Palladium Catalyst for Cross-Couplings of Deactivated (Hetero)aryl Chlorides and Bromides with Arylboronic Acids
  作者：Takashi Hoshi、Tomonobu Honma、Ayako Mori、Maki Konishi、Tsutomu Sato、Hisahiro Hagiwara、Toshio Suzuki

  DOI：10.1021/jo402089r

  日期：2013.11.15

  An active, general, and long-lived palladium catalyst for Suzuki-Miyaura reactions of aryl and heteroaryl chlorides deactivated by steric hindrance, electron richness, and coordinating functional groups is reported. In reactions of arylbromide bearing two o-tert-butyl substituents, C(sp(3))-H arylation of the tert-butyl group, rather than the Suzuki-Miyaura reaction, proceeded in excellent yield. The key to the success of the reactions was the development of biphenylene-substituted dicyclohexylruthenocenylphosphine (CyR-Phos) as a supporting ligand.